Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19
Adrían V. Hernández, Yuani M. Roman, Vinay Pasupuleti, et al.
Annals of Internal Medicine (2020) Vol. 173, Iss. 4, pp. 287-296
Closed Access | Times Cited: 220

Showing 1-25 of 220 citing articles:

COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Soo Lim, Jae Hyun Bae, Hyuk‐Sang Kwon, et al.
Nature Reviews Endocrinology (2020) Vol. 17, Iss. 1, pp. 11-30
Open Access | Times Cited: 925
Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis
Thibault Fiolet, Anthony Guihur, Mathieu E. Rebeaud, et al.
Clinical Microbiology and Infection (2020) Vol. 27, Iss. 1, pp. 19-27
Open Access | Times Cited: 295
Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study
Noa Biran, Andrew Ip, Jaeil Ahn, et al.
The Lancet Rheumatology (2020) Vol. 2, Iss. 10, pp. e603-e612
Open Access | Times Cited: 289
Abnormal Liver Function Tests in Patients With COVID‐19: Relevance and Potential Pathogenesis
Anna Bertolini, Ivo P. van de Peppel, Frank A.J.A. Bodewes, et al.
Hepatology (2020) Vol. 72, Iss. 5, pp. 1864-1872
Open Access | Times Cited: 282
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials
Cathrine Axfors, Andreas M. Schmitt, Perrine Janiaud, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 272
Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers
Benjamin S. Abella, Eliana L. Jolkovsky, Barbara Biney, et al.
JAMA Internal Medicine (2020) Vol. 181, Iss. 2, pp. 195-195
Open Access | Times Cited: 192
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19
Bhagteshwar Singh, Hannah Ryan, Tamara Kredo, et al.
Cochrane library (2021) Vol. 2021, Iss. 2
Open Access | Times Cited: 190
An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies
Kuldeep Dhama, Shailesh Kumar Patel, Mamta Pathak, et al.
Travel Medicine and Infectious Disease (2020) Vol. 37, pp. 101755-101755
Open Access | Times Cited: 180
Association Between Caseload Surge and COVID-19 Survival in 558 U.S. Hospitals, March to August 2020
Sameer S. Kadri, Junfeng Sun, Alexander Lawandi, et al.
Annals of Internal Medicine (2021) Vol. 174, Iss. 9, pp. 1240-1251
Open Access | Times Cited: 169
Methodological quality of COVID-19 clinical research
Richard G. Jung, Pietro Di Santo, Cole Clifford, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 147
RETRACTED ARTICLE: Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study
Hany Dabbous, Sherief Abd‐Elsalam, Manal H. El‐Sayed, et al.
Archives of Virology (2021) Vol. 166, Iss. 3, pp. 949-954
Open Access | Times Cited: 129
Distinct uptake, amplification, and release of SARS-CoV-2 by M1 and M2 alveolar macrophages
Jiadi Lv, Zhenfeng Wang, Yajin Qu, et al.
Cell Discovery (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 129
Combating Oxidative Stress and Inflammation in COVID‐19 by Molecular Hydrogen Therapy: Mechanisms and Perspectives
Duried Alwazeer, Franky Fuh-Ching Liu, Xiao Yu Wu, et al.
Oxidative Medicine and Cellular Longevity (2021) Vol. 2021, Iss. 1
Open Access | Times Cited: 102
SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic
Ali A. Rabaan, Shamsah H. Al-Ahmed, Ranjit Sah, et al.
Annals of Clinical Microbiology and Antimicrobials (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 134
Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis
Zakariya Kashour, Muhammad Riaz, Musa A. Garbati, et al.
Journal of Antimicrobial Chemotherapy (2020) Vol. 76, Iss. 1, pp. 30-42
Open Access | Times Cited: 125
Hydroxychloroquine for the Prevention of Covid-19 — Searching for Evidence
Myron S. Cohen
New England Journal of Medicine (2020) Vol. 383, Iss. 6, pp. 585-586
Open Access | Times Cited: 110
Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study
Augusto Di Castelnuovo, Simona Costanzo, Andrea Antinori, et al.
European Journal of Internal Medicine (2020) Vol. 82, pp. 38-47
Open Access | Times Cited: 110
Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline (updated version)
Yinghui Jin, Qingyuan Zhan, Zhiyong Peng, et al.
Military Medical Research (2020) Vol. 7, Iss. 1
Open Access | Times Cited: 110
Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose
Cassandra R. Doyno, Diana M Sobieraj, William L. Baker
Clinical Toxicology (2020) Vol. 59, Iss. 1, pp. 12-23
Open Access | Times Cited: 95
Botanical drugs and supplements affecting the immune response in the time of COVID‐19: Implications for research and clinical practice
Thomas Brendler, Ahmed Al‐Harrasi, Rudolf Bauer, et al.
Phytotherapy Research (2020) Vol. 35, Iss. 6, pp. 3013-3031
Closed Access | Times Cited: 95
The SARS-CoV-2 Cytopathic Effect Is Blocked by Lysosome Alkalizing Small Molecules
Kirill Gorshkov, Catherine Z. Chen, Robert Bostwick, et al.
ACS Infectious Diseases (2020) Vol. 7, Iss. 6, pp. 1389-1408
Open Access | Times Cited: 86
Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia
Stanley C. Jordan, P. Zakowski, Hai Tran, et al.
Clinical Infectious Diseases (2020) Vol. 71, Iss. 12, pp. 3168-3173
Open Access | Times Cited: 83
Addressing Africa’s pandemic puzzle: Perspectives on COVID-19 transmission and mortality in sub-Saharan Africa
Hassan Hussein Musa, Taha Hussein Musa, Idriss Hussein Musa, et al.
International Journal of Infectious Diseases (2020) Vol. 102, pp. 483-488
Open Access | Times Cited: 77
Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients
Pasquale Paolisso, Luca Bergamaschi, Emanuela Concetta D’Angelo, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 74
Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients
Robert J. Ulrich, Andrea B. Troxel, Ellie Carmody, et al.
Open Forum Infectious Diseases (2020) Vol. 7, Iss. 10
Open Access | Times Cited: 69
Page 1 - Next Page

Scroll to top